Literature DB >> 27848034

Vagus nerve stimulation in psychiatry: a systematic review of the available evidence.

Camelia-Lucia Cimpianu1, Wolfgang Strube2, Peter Falkai2, Ulrich Palm2, Alkomiet Hasan2.   

Abstract

Invasive and non-invasive vagus nerve stimulation (VNS) is a promising add-on treatment for treatment-refractory depression, but is also increasingly evaluated for its application in other psychiatric disorders, such as dementia, schizophrenia, somatoform disorder, and others. We performed a systematic review aiming to give a detailed overview of the available evidence of the efficacy of VNS for the treatment of psychiatric disorders. Data derived from animal models, experimental trials without health-related outcomes, case reports, single-session studies, and reviews were excluded. From 1292 publications, 33 records were included for further analyses: 25 focused on VNS as treatment of unipolar or bipolar major depressive disorder and one investigated the neurocognitive improvement after VNS in major depressive disorder. Seven focused on the improvement of cognitive function in Alzheimer´s disease, improvement of schizophrenia symptoms, treatment of obsessive compulsive disorder (OCD), panic disorder (PD) and post-traumatic stress disorder (PTSD), treatment resistant rapid-cycling bipolar disorder, treatment of fibromyalgia, and Prader-Willi syndrome. A total of 29 studies used invasive VNS, while four studies used non-invasive, transcutaneous VNS. Only 7 out of 33 studies investigated conditions other than affective disorders. The efficacy data of VNS in affective disorders is promising, whereas more in controlled and naturalistic studies are needed. In other conditions like schizophrenia, Alzheimer's disease, OCD, PD, PTSD, and fibromyalgia, either no effects or preliminary data on efficacy were reported. At this point, no final conclusion can be made regarding the efficacy of VNS to improve symptoms in psychiatric disorders other than in affective disorders.

Entities:  

Keywords:  Brain stimulation; Evidence-based psychiatry; Psychiatric disorders; Vagus nerve stimulation

Mesh:

Year:  2016        PMID: 27848034     DOI: 10.1007/s00702-016-1642-2

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  51 in total

Review 1.  Is there a future for therapeutic use of transcranial magnetic stimulation?

Authors:  Michael C Ridding; John C Rothwell
Journal:  Nat Rev Neurosci       Date:  2007-07       Impact factor: 34.870

2.  Reprint--preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  Phys Ther       Date:  2009-09

3.  Transcutaneous auricular vagus nerve stimulation as a complementary therapy for pediatric epilepsy: a pilot trial.

Authors:  Wei He; Xianghong Jing; Xiaoyu Wang; Peijing Rong; Liang Li; Hong Shi; Hongyan Shang; Yuping Wang; Jianguo Zhang; Bing Zhu
Journal:  Epilepsy Behav       Date:  2013-06-29       Impact factor: 2.937

4.  Transcutaneous vagus nerve stimulation (t-VNS) in pharmacoresistant epilepsies: a proof of concept trial.

Authors:  Hermann Stefan; Gernot Kreiselmeyer; Frank Kerling; Katrin Kurzbuch; Christophe Rauch; Marcel Heers; Burkhard S Kasper; Thilo Hammen; Martina Rzonsa; Elisabeth Pauli; Jens Ellrich; Wolfgang Graf; Rüdiger Hopfengärtner
Journal:  Epilepsia       Date:  2012-05-03       Impact factor: 5.864

5.  Transcutaneous vagus nerve stimulation modulates amygdala functional connectivity in patients with depression.

Authors:  Jun Liu; Jiliang Fang; Zengjian Wang; Peijing Rong; Yang Hong; Yangyang Fan; Xiaoling Wang; Joel Park; Yu Jin; Chunhong Liu; Bing Zhu; Jian Kong
Journal:  J Affect Disord       Date:  2016-08-11       Impact factor: 4.839

6.  Chronic vagus nerve stimulation for treatment-resistant depression increases regional cerebral blood flow in the dorsolateral prefrontal cortex.

Authors:  Markus Kosel; Holger Brockmann; Caroline Frick; Astrid Zobel; Thomas E Schlaepfer
Journal:  Psychiatry Res       Date:  2011-03-31       Impact factor: 3.222

7.  Brain blood-flow alterations induced by therapeutic vagus nerve stimulation in partial epilepsy: II. prolonged effects at high and low levels of stimulation.

Authors:  Thomas R Henry; Roy A E Bakay; Page B Pennell; Charles M Epstein; John R Votaw
Journal:  Epilepsia       Date:  2004-09       Impact factor: 5.864

8.  Vagus nerve stimulation for depression: efficacy and safety in a European study.

Authors:  T E Schlaepfer; C Frick; A Zobel; W Maier; I Heuser; M Bajbouj; V O'Keane; C Corcoran; R Adolfsson; M Trimble; H Rau; H-J Hoff; F Padberg; F Müller-Siecheneder; K Audenaert; D Van den Abbeele; K Matthews; D Christmas; Z Stanga; M Hasdemir
Journal:  Psychol Med       Date:  2008-01-04       Impact factor: 7.723

9.  Vagus nerve stimulation for treatment-resistant mood disorders: a long-term naturalistic study.

Authors:  Umberto Albert; Giuseppe Maina; Andrea Aguglia; Alberto Vitalucci; Filippo Bogetto; Chiara Fronda; Alessandro Ducati; Michele Lanotte
Journal:  BMC Psychiatry       Date:  2015-03-31       Impact factor: 3.630

10.  Mortality and suicide risk in treatment-resistant depression: an observational study of the long-term impact of intervention.

Authors:  Bryan Olin; Amara K Jayewardene; Mark Bunker; Francisco Moreno
Journal:  PLoS One       Date:  2012-10-25       Impact factor: 3.240

View more
  28 in total

Review 1.  Neural engineering: the process, applications, and its role in the future of medicine.

Authors:  Evon S Ereifej; Courtney E Shell; Jonathon S Schofield; Hamid Charkhkar; Ivana Cuberovic; Alan D Dorval; Emily L Graczyk; Takashi D Y Kozai; Kevin J Otto; Dustin J Tyler; Cristin G Welle; Alik S Widge; José Zariffa; Chet T Moritz; Dennis J Bourbeau; Paul D Marasco
Journal:  J Neural Eng       Date:  2019-11-12       Impact factor: 5.379

Review 2.  Ketamine: Leading us into the future for development of antidepressants.

Authors:  Flavia R Carreno; Daniel J Lodge; Alan Frazer
Journal:  Behav Brain Res       Date:  2020-02-02       Impact factor: 3.332

Review 3.  Contribution of Baroreceptor Function to Pain Perception and Perioperative Outcomes.

Authors:  Heberto Suarez-Roca; Rebecca Y Klinger; Mihai V Podgoreanu; Ru-Rong Ji; Martin I Sigurdsson; Nathan Waldron; Joseph P Mathew; William Maixner
Journal:  Anesthesiology       Date:  2019-04       Impact factor: 7.892

Review 4.  Executive Summary: Collected Papers of the American College of Surgeons Metabolic Surgery Symposium.

Authors:  Henry Buchwald; J N Buchwald; Walter J Pories; David B Hoyt
Journal:  Obes Surg       Date:  2020-05       Impact factor: 4.129

Review 5.  Finding intestinal fortitude: Integrating the microbiome into a holistic view of depression mechanisms, treatment, and resilience.

Authors:  M C Flux; Christopher A Lowry
Journal:  Neurobiol Dis       Date:  2019-08-24       Impact factor: 5.996

Review 6.  Vagal Nerve Stimulation for Treatment-Resistant Depression.

Authors:  Flavia R Carreno; Alan Frazer
Journal:  Neurotherapeutics       Date:  2017-07       Impact factor: 7.620

7.  Auricular vagus nerve stimulator for closed-loop biofeedback-based operation.

Authors:  Babak Dabiri; Klaus Zeiner; Arnaud Nativel; Eugenijus Kaniusas
Journal:  Analog Integr Circuits Signal Process       Date:  2022-05-10       Impact factor: 1.321

Review 8.  Targeting neural oscillations with transcranial alternating current stimulation.

Authors:  Justin Riddle; Flavio Frohlich
Journal:  Brain Res       Date:  2021-04-20       Impact factor: 3.610

9.  Reinstatement of contextual conditioned anxiety in virtual reality and the effects of transcutaneous vagus nerve stimulation in humans.

Authors:  Hannah Genheimer; Marta Andreatta; Esther Asan; Paul Pauli
Journal:  Sci Rep       Date:  2017-12-20       Impact factor: 4.379

Review 10.  Neuroimmune Interactions in Schizophrenia: Focus on Vagus Nerve Stimulation and Activation of the Alpha-7 Nicotinic Acetylcholine Receptor.

Authors:  Fabiana Maria das Graças Corsi-Zuelli; Fernanda Brognara; Gustavo Fernando da Silva Quirino; Carlos Hiroji Hiroki; Rafael Sobrano Fais; Cristina Marta Del-Ben; Luis Ulloa; Helio Cesar Salgado; Alexandre Kanashiro; Camila Marcelino Loureiro
Journal:  Front Immunol       Date:  2017-05-31       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.